{"id":67329,"date":"2026-06-04T19:58:11","date_gmt":"2026-06-04T11:58:11","guid":{"rendered":"https:\/\/flcube.com\/?p=67329"},"modified":"2026-06-04T19:58:12","modified_gmt":"2026-06-04T11:58:12","slug":"yunnan-baiyao-secures-fda-clinical-approval-for-inb301-in-tumor-cachexia-first-chinese-tcm-company-to-advance-novel-therapy-in-us-oncology-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67329","title":{"rendered":"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Yunnan Baiyao Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000538:SHE\">SHE: 000538<\/a>), a leading <strong>traditional Chinese medicine (TCM)<\/strong> company, announced it has received <strong>clinical trial approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for its investigational agent <strong>INB301<\/strong>, targeting <strong>tumor cachexia<\/strong>\u2014a debilitating metabolic disorder affecting cancer patients worldwide.<\/p>\n\n\n\n<h2 id=\"h-regulatory-achievement-amp-strategic-significance\" class=\"wp-block-heading\">Regulatory Achievement &amp; Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Yunnan Baiyao Group Co., Ltd. (SHE: 000538)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND) application clearance<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>INB301 (novel therapeutic agent)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Tumor cachexia in cancer patients<\/td><\/tr><tr><td><strong>Strategic Milestone<\/strong><\/td><td>First Chinese TCM company to secure FDA clinical approval for a novel oncology indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This approval marks a significant departure from Yunnan Baiyao&#8217;s traditional TCM product portfolio, demonstrating the company&#8217;s successful transition into evidence-based, globally regulated pharmaceutical development.<\/p>\n\n\n\n<h2 id=\"h-disease-profile-amp-unmet-medical-need\" class=\"wp-block-heading\">Disease Profile &amp; Unmet Medical Need<\/h2>\n\n\n\n<h3 id=\"h-tumor-cachexia-overview\" class=\"wp-block-heading\">Tumor Cachexia Overview<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Definition:<\/strong> Complex metabolic disorder syndrome triggered by malignant tumors<\/li>\n\n\n\n<li><strong>Primary Characteristic:<\/strong> Persistent skeletal muscle wasting that cannot be reversed through conventional nutritional support<\/li>\n\n\n\n<li><strong>Prevalence:<\/strong> Affects 50-80% of advanced cancer patients<\/li>\n\n\n\n<li><strong>Clinical Impact:<\/strong><\/li>\n\n\n\n<li>Contributes to 20-30% of cancer-related deaths<\/li>\n\n\n\n<li>Reduces treatment tolerance and quality of life<\/li>\n\n\n\n<li>Associated with poor response to anti-cancer therapies<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> No FDA-approved therapies specifically targeting tumor cachexia<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-challenge\" class=\"wp-block-heading\">Therapeutic Challenge<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The condition represents one of oncology&#8217;s most persistent unmet needs, with existing interventions limited to palliative nutritional support that fails to address the underlying metabolic dysregulation driving muscle catabolism.<\/p>\n\n\n\n<h2 id=\"h-innovation-amp-development-strategy\" class=\"wp-block-heading\">Innovation &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Mechanism:<\/strong> INB301 represents a targeted approach to modulating the complex inflammatory and metabolic pathways underlying cachexia<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> FDA approval enables international clinical trials and potential worldwide commercialization<\/li>\n\n\n\n<li><strong>TCM Modernization:<\/strong> Leverages traditional Chinese medicine principles while adhering to Western regulatory standards<\/li>\n\n\n\n<li><strong>Oncology Expansion:<\/strong> Positions Yunnan Baiyao as a serious player in the global oncology supportive care market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Estimated 1.8 million cancer patients annually in the US develop significant cachexia<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Potential $3-5 billion annual market if effective therapy demonstrates survival and quality-of-life benefits<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> First-mover status in a therapeutic area with no approved disease-modifying treatments<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Orphan-like indication with high unmet need supports premium pricing strategy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The successful navigation of FDA regulatory requirements demonstrates Yunnan Baiyao&#8217;s capability to develop globally competitive pharmaceutical products while maintaining its TCM heritage.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications-for-chinese-pharma\" class=\"wp-block-heading\">Strategic Implications for Chinese Pharma<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Validation:<\/strong> FDA approval provides international credibility for Chinese pharmaceutical innovation<\/li>\n\n\n\n<li><strong>Investment Attraction:<\/strong> Opens doors to global partnerships and capital markets<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Establishes precedent for other Chinese companies seeking US market entry<\/li>\n\n\n\n<li><strong>Innovation Model:<\/strong> Demonstrates successful integration of traditional medicine concepts with modern drug development paradigms<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and market opportunities for INB301. Actual results may differ materially due to clinical trial outcomes, regulatory decisions, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e91\u5357\u767d\u836f\uff1a\u5173\u4e8eINB301\u6ce8\u5c04\u6db2\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e91\u5357\u767d\u836f\uff1a\u5173\u4e8eINB301\u6ce8\u5c04\u6db2\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-8dc09bff-b2a7-4f6b-9d24-73a308351646\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e91\u5357\u767d\u836f\uff1a\u5173\u4e8eINB301\u6ce8\u5c04\u6db2\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\u7684\u516c\u544a.pdf\">\u4e91\u5357\u767d\u836f\uff1a\u5173\u4e8eINB301\u6ce8\u5c04\u6db2\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u4e91\u5357\u767d\u836f\uff1a\u5173\u4e8eINB301\u6ce8\u5c04\u6db2\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8dc09bff-b2a7-4f6b-9d24-73a308351646\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1303,591],"class_list":["post-67329","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-she-000538","tag-yunnan-baiyao"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational agent INB301, targeting tumor cachexia\u2014a debilitating metabolic disorder affecting cancer patients worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67329\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market\" \/>\n<meta property=\"og:description\" content=\"Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational agent INB301, targeting tumor cachexia\u2014a debilitating metabolic disorder affecting cancer patients worldwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67329\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T11:58:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-04T11:58:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67329#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67329\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market\",\"datePublished\":\"2026-06-04T11:58:11+00:00\",\"dateModified\":\"2026-06-04T11:58:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67329\"},\"wordCount\":492,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHE: 000538\",\"Yunnan Baiyao\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67329#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67329\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67329\",\"name\":\"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-04T11:58:11+00:00\",\"dateModified\":\"2026-06-04T11:58:12+00:00\",\"description\":\"Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational agent INB301, targeting tumor cachexia\u2014a debilitating metabolic disorder affecting cancer patients worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67329#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67329\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67329#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market - Insight, China&#039;s Pharmaceutical Industry","description":"Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational agent INB301, targeting tumor cachexia\u2014a debilitating metabolic disorder affecting cancer patients worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67329","og_locale":"en_US","og_type":"article","og_title":"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market","og_description":"Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational agent INB301, targeting tumor cachexia\u2014a debilitating metabolic disorder affecting cancer patients worldwide.","og_url":"https:\/\/flcube.com\/?p=67329","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-04T11:58:11+00:00","article_modified_time":"2026-06-04T11:58:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67329#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67329"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market","datePublished":"2026-06-04T11:58:11+00:00","dateModified":"2026-06-04T11:58:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67329"},"wordCount":492,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHE: 000538","Yunnan Baiyao"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67329#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67329","url":"https:\/\/flcube.com\/?p=67329","name":"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-04T11:58:11+00:00","dateModified":"2026-06-04T11:58:12+00:00","description":"Yunnan Baiyao Group Co., Ltd. (SHE: 000538), a leading traditional Chinese medicine (TCM) company, announced it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its investigational agent INB301, targeting tumor cachexia\u2014a debilitating metabolic disorder affecting cancer patients worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67329#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67329"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67329#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia \u2013 First Chinese TCM Company to Advance Novel Therapy in US Oncology Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67329"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67329\/revisions"}],"predecessor-version":[{"id":67331,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67329\/revisions\/67331"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}